Veracyte (VCYT) EBITDA (2012 - 2026)

Veracyte has reported EBITDA for 15 years, with the latest figure at $23.0 million in Q2 2026.

• EBITDA for Q2 2026 came in at $23.0 million, up 536.22% year-over-year; the trailing twelve-month figure through Jun 2026 was $105.8 million (up 664.88% YoY), and the FY2025 annual result was $57.8 million, up 257.93% from the prior year.
• EBITDA grew to $23.0 million in Q2 2026, from $22.6 million in the prior quarter.
• Over five years, EBITDA peaked at $37.2 million in Q4 2025 and troughed at -$35.5 million in Q4 2023.
• A 5-year average of -$407277.8 and a median of -$5.0 million in 2024 frame the typical range for EBITDA.
• The widest annual swing landed in 2023, when EBITDA sank 555.11%; it then soared 790.9% in 2025.
• A 5-year view of EBITDA shows it stood at -$5.4 million in 2022, then sank by 555.11% to -$35.5 million in 2023, then soared by 111.76% to $4.2 million in 2024, then soared by 790.9% to $37.2 million in 2025, then plunged by 38.22% to $23.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $23.0 million in Q2 2026, $22.6 million in Q1 2026, and $37.2 million in Q4 2025.